Comparing ProSomnus (OSA) & Its Competitors

ProSomnus (NASDAQ:OSA) is one of 221 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare ProSomnus to similar businesses based on the strength of its dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares ProSomnus and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProSomnus	-87.14%	N/A	-106.30%
ProSomnus Competitors	-772.65%	-154.89%	-30.47%

Insider & Institutional Ownership

70.0% of ProSomnus shares are held by institutional investors. Comparatively, 47.3% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 7.7% of ProSomnus shares are held by company insiders. Comparatively, 15.7% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ProSomnus and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProSomnus	$27.65 million	-$24.09 million	-0.10
ProSomnus Competitors	$915.00 million	$6.84 million	-5.61

ProSomnus’ peers have higher revenue and earnings than ProSomnus. ProSomnus is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for ProSomnus and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProSomnus	0	1	2	0	2.67
ProSomnus Competitors	1451	3995	7824	193	2.50

ProSomnus presently has a consensus target price of $2.33, indicating a potential upside of 1,455.56%. As a group, “Surgical & medical instruments” companies have a potential upside of 31.53%. Given ProSomnus’ stronger consensus rating and higher probable upside, analysts plainly believe ProSomnus is more favorable than its peers.

Volatility & Risk

ProSomnus has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ peers have a beta of 1.44, meaning that their average stock price is 44% more volatile than the S&P 500.

Summary

ProSomnus beats its peers on 7 of the 13 factors compared.

ProSomnus Company Profile

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.